

LIPACS-PAT: PRESCRIPTION SUPPORT TOOL FOR LIPID- LOWERING THERAPY AFTER ACUTE CORONARY SYNDROME

DESCRIPTION OF THE TECHNOLOGY

Patients who experience an **acute coronary syndrome (ACS)** require an appropriate selection of **lipid-lowering therapies** to achieve the recommended **low-density lipoprotein cholesterol (LDL-C)** targets for secondary cardiovascular prevention. However, the wide range of available therapeutic options differs substantially in terms of clinical efficacy and cost within the Spanish National Health System. Despite treatment prescribed at hospital discharge, **more than 60% of patients fail to achieve the recommended LDL-C target**, while real-world European registries indicate that **only 30% maintain optimal LDL-C levels** during follow-up.

Although scientific evidence and educational tools are available to estimate the expected LDL-C reduction achieved with different lipid-lowering therapies, existing solutions do not provide an integrated comparison of the available therapeutic options or incorporate **cost-effectiveness criteria**.

Researchers at INCLIVA have developed **LIPACS-PAT, a web-based prescription support tool** designed to assist clinicians in selecting the most appropriate lipid-lowering therapy following an acute coronary syndrome. The platform integrates all available therapeutic options into a **single interface** and enables personalised treatment scenarios to be explored according to baseline LDL-C levels, current lipid-lowering therapy and the desired therapeutic target.

Furthermore, LIPACS-PAT enables the **extrapolation of baseline LDL-C values** based on the patient's current treatment and incorporates cost-effectiveness information, allowing available therapeutic options to be prioritised according to their expected clinical and economic value.

APPLICATION

Healthcare / Medical education

Specialties: Cardiology, Internal Medicine, Neurology, Vascular Surgery and Cardiac Surgery.

COLABORATION SOUGHT

Digital health and healthcare software companies interested in licensing or co-development agreements.

Hospitals and healthcare organisations interested in validating the technology.

ADVANTAGES

- ✓ Integration of multiple lipid-lowering therapeutic strategies into a single platform.
- ✓ Personalised evaluation based on baseline LDL-C levels and previous treatment.
- ✓ Prioritisation of therapeutic options according to cost-effectiveness.
- ✓ Educational tool supporting evidence-based prescribing.

STATE OF DEVELOPMENT

LIPACS-PAT has been developed as a web-based platform and is currently undergoing preclinical validation through simulated clinical cases to evaluate its impact in a cohort of cardiologists. Upon completion of this phase, the platform will be available for educational purposes. Future clinical implementation will require further development as a regulated medical device.

INTELLECTUAL PROPERTY RIGHTS

Software registered on 23 February 2026 under registration number SFW2026_01.

CONTACT

INCLIVA Innovation Unit

+34 961 628 922 / 961 628 923

innovacion@incliva.es

LIPACS-PAT
Lipid-lowering therapies after an Acute Coronary Syndrome - Prescription Assistance Tool

Niveles de lípidos
LDL Colesterol: 100 mg/dL
LDL Objetivo: 50 mg/dL

Opciones de cálculo
Cálculo basado en la reducción del 50% del nivel: Sí

LDL Basal estimado: 175.4 mg/dL

Tratamiento previo
Estadina (rosuvastatina o atorvastatina): 20 mg

Tratamiento actual
Estadina: 20 mg

% Reducción Necesaria: 45.0%

LDL-C objetivo considerando la regla del 80%: 87.7 mg/dL

Mejores alternativas terapéuticas para cumplir el objetivo terapéutico propuesto (ordenadas por precio)

#	Tratamiento	% Reducción	Precio	Prevalencia	LDL-C esperado
1	Rosuvastatina 40mg + Ezetimibe 10 mg	71%	27.52 €	6.9172	60.9 mg/dL (1.57 mmol/L)
2	Atorvastatina 80mg + Ácido Bempedoico 180 mg / Ezetimibe 10 mg	71%	107.83 €	3.5526	60.9 mg/dL (1.57 mmol/L)
3	Indinavir + Estatina alta potencia	70%	198.57 €	7.0179	61.9 mg/dL (1.59 mmol/L)
4	Indinavir + Estatina alta potencia + Fibrato	88%	181.92 €	2.2895	26.3 mg/dL (0.68 mmol/L)
5	Indinavir + Estatina alta potencia + Ácido Bempedoico 180 mg / Ezetimibe 10 mg	88%	261.76 €	10.3675	29.1 mg/dL (0.75 mmol/L)
6	Fibrato + Estatina alta potencia	75%	510.37 €	18.1775	41.9 mg/dL (1.08 mmol/L)
7	Atorvastatina 100-mg + alta potencia	75%	510.37 €	18.1775	41.9 mg/dL (1.08 mmol/L)
8	Rosuvastatina + Estatina alta potencia + Fibrato 10mg	85%	517.39 €	18.4782	35.3 mg/dL (0.91 mmol/L)
9	Atorvastatina 100-mg + alta potencia + Fibrato 10mg	85%	517.39 €	18.4782	35.3 mg/dL (0.91 mmol/L)
10	Bempedoico + Estatina alta potencia + Ácido Bempedoico 180 mg / Fibrato 10 mg	88%	188.91 €	21.2219	29.1 mg/dL (0.75 mmol/L)
11	Atorvastatina 100-mg + alta potencia + Ácido Bempedoico 180 mg / Ezetimibe 10 mg	88%	188.91 €	21.2219	29.1 mg/dL (0.75 mmol/L)